Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2007

View Archived Issues

BIBW-2992 active in preclinical models and patients with non-small cell lung cancer

Natural products for the treatment of sleep disorders

Motexafin gadolinium studied in refractory lung cancer, patients with brain metastases

Intra-Cellular Therapies outlines portfolio of proprietary compounds for FSD

LigoCyte to develop anti-CD103 therapies with Biogen Idec

Positive results for sanofi pasteur's low-dose H5N1 influenza vaccine

Recent patents disclose novel therapeutic agents for cardiovascular disorders

Discovery of agents for neurological disorders reported in recent patent literature

MKC-1 well tolerated in phase II metastatic breast cancer trial

Knee osteoarthritis pain relief observed with IDEA-033

Preclinical antianginal activity of the sodium channel blocker F-15845

Preclinical characterization of DX-2400, a novel fully human antibody against MMP-14

Preclinical activity and pharmacokinetics of the novel PDE5 inhibitor lodenafil carbonate

Astellas Pharma U.S. submits response to FDA action letter for once-daily FK-506

Alexza to begin first of two phase III trials of AZ-004

FDA recommends LipoNova continue autologous RCC vaccine development program

Allergan to acquire Esprit Pharma and partner with Indevus on Sanctura brand

GlaxoSmithKline submits application for SAD indication for Paxil tablet in Japan

PEGylation and Pulmonary research units created by Nektar

Evotec to acquire Renovis

Patient enrollment completed in phase II trial of Gabapentin GR for menopausal hot flashes

AVI BioPharma receives DoD contract for development of NeuGene antisense drug

DelSite Biotechnologies enters technology evaluation agreement for GelSite polymer

RDEA-806: a novel anti-HIV NNRTI safe and well tolerated in human studies

TMC-125 NDA accepted for priority review in U.S.

Campath approved in U.S. for first-line treatment for B-CLL

Novel antifolates with improved activity against staphylococcal and enterococcal infections

Lilly files for European approval of Alimta as first-line treatment of NSCLC

Wyeth receives EMEA opinions on Torisel and Mylotarg

The EC to authorize Yondelis commercialization for soft tissue carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...